About MRC-Holland
MRC-Holland b.v. is a biotechnology company located in Amsterdam, the Netherlands. The company is a follow-up of Microbiology Research Centre Holland, founded in 1985 by Dr. Jan Schouten. Until 2000, the main products of MRC-Holland were restriction endonucleases -purified from a wide range of bacteria and blue green algae- and DNA molecular weight markers. These products were sold in bulk amounts to distributing companies worldwide.

In 1997, MRC-Holland started focusing on developing new techniques for DNA analysis. By far the most successful technique developed is Multiplex Ligation-dependent Probe Amplification, or MLPA®. The MLPA® technology was first described in Nucleic Acid Research 30, e57 (2002) by Schouten et al. Since then, hundreds of MLPA probe sets have been developed for a wide variety of genes and applications, some of which very rare.

At present, all activities of MRC-Holland are directed to the production of new MLPA-based products and the development of novel MLPA-based techniques. MRC-Holland currently has about 70 employees, working in development, quality testing, production, sales and customer service.

MRC-Holland office
new products
P520-MPN mix 2
Myeloproliferative neoplasms
improved products
P083-CDH1
Hereditary diffuse gastric cancer
P066-Marfan Syndrome-2
Marfan syndrome
P065-Marfan Syndrome-1
Marfan syndrome
P081-NF1 mix 1
Neurofibromatosis
P262-GHI
Growth Hormone Insensitivity (GHI)
P264-Human Telomere-9
Subtelomeric testing
Newsletter  |  Home  |  Site map  |  Terms and Conditions  |  Search  |  Copyright © 2017 MRC-Holland